Form 4: Verona Pharma Executive Kathleen A. Rickard Sells Shares Under 10b5-1 Plan

Kathleen A. Rickard, Chief Medical Officer of Verona Pharma plc, sold 79,264 ordinary shares at an average price of $8.3511, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Kathleen A. Rickard, the Chief Medical Officer of Verona Pharma plc, reported a transaction involving the sale of ordinary shares.
• The transaction occurred on March 12, 2025.
• Rickard sold 79,264 ordinary shares at a weighted average price of $8.3511 per share.
• The sale was executed under a Rule 10b5-1 plan adopted on December 11, 2024.
• Following the transaction, Rickard beneficially owns 2,608,976 ordinary shares.
• These shares include those underlying Restricted Share Units and ADSs (American Depositary Shares).

Sentiment

Score: 5

Explanation: The document reports a routine transaction (executive share sale under a pre-arranged plan). It doesn't inherently indicate positive or negative sentiment.

Industry Context

Executive share sales are a common occurrence in publicly traded companies. The use of a 10b5-1 plan allows insiders to sell shares over a predetermined period, mitigating concerns about trading on inside information.

Stakeholder Impact

• The share sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates